Health & TechThe FDA granted accelerated approval to Rybrevant Faspro for head and neck cancer
In a 102-patient trial, subcutaneous amivantamab, sold as Rybrevant Faspro, produced a 42 percent overall response rate in recurrent or metastatic head and neck cancer after chemo and immunotherapy. Confirmatory studies are required.
Verified · U.S. Food and Drug Administration





















